Amir Mortazavi

Amir Mortazavi

Auto-generated profile, based on publicly available information

Amir Mortazavi

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2018 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
BABesma Abbaoui
Besma Abbaoui
CLChristopher R. Lucas
Christopher R. Lucas
KRKen Riedl
Ken Riedl
SCSteven K. Clinton
Steven K. Clinton
AMAmir Mortazavi
Amir Mortazavi

1 November 2020 in Journal of Clinical Oncology
Verified
Journal Article
Open access
AAAndrea Apolo
Andrea Apolo
RNRosa Nadal
Rosa Nadal
DGDaniel Girardi
Daniel Girardi
SNScot A. Niglio
Scot A. Niglio
LLLisa Ley
Lisa Ley
AMAmir Mortazavi
Amir Mortazavi
PURPOSE: We assessed the safety and efficacy of cabozantinib and nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignances. PATIENTS AND METHODS: Patients received escalating doses of CaboNivo or CaboNivoIpi. The primary objective was to establish a recommended phase II dose (RP2D). Secondary objectives included objective response rate (ORR), progression-free survival (PFS), duration of response (DoR), and overall survival (OS). RESULTS: Fifty-four patients were enrolled at eight dose levels with a median follow-up time of 44.6 months; data cutoff was January 20, 2020. Grade 3 or 4 treatment-related adverse events (AEs) occurred in 75% and 87% of patients treated with CaboNivo and CaboNivoIpi, respectively, and included fatigue (17% and 10%, respectively), diarrhea (4% and 7%, respectively), and hypertension (21% and 10%, respectively); grade 3 or 4 immune-related AEs included hepatitis (0% and 13%, respectively) and colitis (0% and 7%, respectively). The RP2D was cabozantinib 40 mg/d plus nivolumab 3 mg/kg for CaboNivo and cabozantinib 40 mg/d, nivolumab 3 mg/kg, and ipilimumab 1 mg/kg for CaboNivoIpi. ORR was 30.6% (95% CI, 20.0% to 47.5%) for all patients and 38.5% (95% CI, 13.9% to 68.4%) for patients with mUC. Median DoR was 21.0 months (95% CI, 5.4 to 24.1 months) for all patients and not reached for patients with mUC. Median PFS was 5.1 months (95% CI, 3.5 to 6.9 months) for all patients and 12.8 months (95% CI, 1.8 to 24.1 months) for patients with mUC. Median OS was 12.6 months (95% CI, 6.9 to 18.8 months) for all patients and 25.4 months (95% CI, 5.7 to 41.6 months) for patients with mUC. CONCLUSION: CaboNivo and CaboNivoIpi demonstrated manageable toxicities with durable responses and encouraging survival in patients with mUC and other GU tumors. Multiple phase II and III trials are ongoing for these combinations.

28 January 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SFSamuel A. Funt
Samuel A. Funt
MLMichael Lattanzi
Michael Lattanzi
KWKarissa Whiting
Karissa Whiting
HAHikmat A. Al-Ahmadie
Hikmat A. Al-Ahmadie
CQColleen Quinlan
Colleen Quinlan
JRJonathan E. Rosenberg
Jonathan E. Rosenberg
PURPOSE: Neoadjuvant gemcitabine and cisplatin (GC) followed by radical cystectomy (RC) is standard for patients with muscle-invasive bladder cancer (MIBC). On the basis of the activity of atezolizumab (A) in metastatic BC, we tested neoadjuvant GC plus A for MIBC. METHODS: Eligible patients with MIBC (cT2-T4aN0M0) received a dose of A, followed 2 weeks later by GC plus A every 21 days for four cycles followed 3 weeks later by a dose of A before RC. The primary end point was non–muscle-invasive downstaging to < pT2N0. RESULTS: Of 44 enrolled patients, 39 were evaluable. The primary end point was met, with 27 of 39 patients (69%) < pT2N0, including 16 (41%) pT0N0. No patient with < pT2N0 relapsed and four (11%) with ≥ pT2N0 relapsed with a median follow-up of 16.5 months (range: 7.0-33.7 months). One patient refused RC and two developed metastatic disease before RC; all were considered nonresponders. The most common grade 3-4 adverse event (AE) was neutropenia (n = 16; 36%). Grade 3 immune-related AEs occurred in five (11%) patients with two (5%) requiring systemic steroids. The median time from last dose of chemotherapy to surgery was 7.8 weeks (range: 5.1-17 weeks), and no patient failed to undergo RC because of AEs. Four of 39 (10%) patients had programmed death-ligand 1 (PD-L1)–positive tumors and were all < pT2N0. Of the patients with PD-L1 low or negative tumors, 23 of 34 (68%) achieved < pT2N0 and 11 of 34 (32%) were ≥ pT2N0 ( P = .3 for association between PD-L1 and < pT2N0). CONCLUSION: Neoadjuvant GC plus A is a promising regimen for MIBC and warrants further study. Patients with < pT2N0 experienced improved relapse-free survival. The PD-L1 positivity rate was low compared with published data, which limits conclusions regarding PD-L1 as a predictive biomarker.

22 December 2023 in Cells
Verified
Journal Article
Open access
PDF file
LMLingbin Meng
Lingbin Meng
KCKatharine A. Collier
Katharine A. Collier
PWPeng Wang
Peng Wang
ZLZihai Li
Zihai Li
PMPaul Monk
Paul Monk
YYYuanquan Yang
Yuanquan Yang
The most common subtype of renal cell carcinoma is clear cell renal cell carcinoma (ccRCC). While localized ccRCC can be cured with surgery, metastatic disease has a poor prognosis. Recently, immunotherapy has emerged as a promising approach for advanced ccRCC. This review provides a comprehensive overview of the evolving immunotherapeutic landscape for metastatic ccRCC. Immune checkpoint inhibitors (ICIs) like PD-1/PD-L1 and CTLA-4 inhibitors have demonstrated clinical efficacy as monotherapies and in combination regimens. Combination immunotherapies pairing ICIs with antiangiogenic agents, other immunomodulators, or novel therapeutic platforms such as bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy are areas of active research. Beyond the checkpoint blockade, additional modalities including therapeutic vaccines, cytokines, and oncolytic viruses are also being explored for ccRCC. This review discusses the mechanisms, major clinical trials, challenges, and future directions for these emerging immunotherapies. While current strategies have shown promise in improving patient outcomes, continued research is critical for expanding and optimizing immunotherapy approaches for advanced ccRCC. Realizing the full potential of immunotherapy will require elucidating mechanisms of response and resistance, developing predictive biomarkers, and rationally designing combination therapeutic regimens tailored to individual patients. Advances in immunotherapy carry immense promise for transforming the management of metastatic ccRCC.

5 October 2012 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
BABesma Abbaoui
Besma Abbaoui
KRKenneth M. Riedl
Kenneth M. Riedl
RRRobin A. Ralston
Robin A. Ralston
JTJennifer Thomas-Ahner
Jennifer Thomas-Ahner
SSSteven Schwartz
Steven Schwartz
AMAmir Mortazavi
Amir Mortazavi

1 March 2017 in Journal of Proteomics
Verified
Journal Article
Closed access
BABesma Abbaoui
Besma Abbaoui
KTKelly H. Telu
Kelly H. Telu
CLChristopher R. Lucas
Christopher R. Lucas
JTJennifer Thomas-Ahner
Jennifer Thomas-Ahner
SSSteven J. Schwartz
Steven J. Schwartz
AMAmir Mortazavi
Amir Mortazavi